Skip Navigation Link
NCI-60 Screening


The Developmental Therapeutics Program (DTP) operates a progressive, tiered in vitro and in vivo anti-cancer compound screening program for single pure compounds with the goal of identifying and evaluating novel chemical leads and biological mechanisms of action. The program does not support screening of chemical libraries. The DTP screens include the NCI 60 cell line screen and, as appropriate, the hollow fiber assay and relevant human tumor xenograft and rodent tumor models. Information on the experimental details for the screens, the overall DTP testing paradigm, instructions on submitting compounds and the execution of confidentiality agreements with NCI can be found at the links below.

Screening Information

In VitroTesting

In VivoTesting

The following document is in Adobe PDF format.
Get Adobe Acrobat Reader

Anti-Cancer Screening Paradigm

Discreet Screening Agreement

Submission of Purified Compounds